Mara Y Roth1, Kat Lin2, Katrine Bay3, John K Amory4, Bradley D Anawalt4, Alvin M Matsumoto5, Brett T Marck6, William J Bremner4, Stephanie T Page4. 1. Center for Research in Reproduction and Contraception, Department of Medicine, University of Washington, Seattle, Washington. Electronic address: mylang@u.washington.edu. 2. Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington. 3. University Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark. 4. Center for Research in Reproduction and Contraception, Department of Medicine, University of Washington, Seattle, Washington. 5. Center for Research in Reproduction and Contraception, Department of Medicine, University of Washington, Seattle, Washington; Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington. 6. Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
Abstract
OBJECTIVE: To study the potential role for using serum biomarkers, including insulin-like factor 3 (INSL3), 17α-hydroxyprogesterone, antimüllerian hormone, and inhibin B, as correlates of intratesticular T (IT-T) concentrations in men. DESIGN: Prospective, randomized, controlled trial. SETTING: University-based medical center. PATIENT(S): Thirty-seven healthy men aged 18-50 years. INTERVENTION(S): All men received the GnRH antagonist acyline, plus very low doses of hCG (0 IU, 15 IU, 60 IU, or 125 IU) SC every other day or 7.5 g T gel daily (75 mg delivered). The IT-T concentrations obtained by percutaneous testicular aspiration with simultaneous serum protein and steroid concentrations were measured at baseline and after 10 days of treatment. MAIN OUTCOME MEASURE(S): Intratesticular and serum hormone and gonadotropin concentrations. RESULT(S): After 10 days of gonadotropin suppression, serum INSL3 decreased by more than 90% and correlated highly with IT-T concentrations. In contrast, serum inhibin B, antimüllerian hormone, and 17α-hydroxyprogesterone did not correlate with IT-T. Serum INSL3 increased with the dose of hCG administered and returned to baseline after treatment. CONCLUSION(S): Serum INSL3 correlates highly with IT-T and serum T concentrations during acute gonadotropin suppression in men. Human chorionic gonadotropin stimulates dose-dependent increases in INSL3 and IT-T in healthy men and might be a useful biomarker of IT-T concentration in some clinical settings. CLINICAL TRIAL REGISTRATION NUMBER: NCT# 00839319.
RCT Entities:
OBJECTIVE: To study the potential role for using serum biomarkers, including insulin-like factor 3 (INSL3), 17α-hydroxyprogesterone, antimüllerian hormone, and inhibin B, as correlates of intratesticular T (IT-T) concentrations in men. DESIGN: Prospective, randomized, controlled trial. SETTING: University-based medical center. PATIENT(S): Thirty-seven healthy men aged 18-50 years. INTERVENTION(S): All men received the GnRH antagonist acyline, plus very low doses of hCG (0 IU, 15 IU, 60 IU, or 125 IU) SC every other day or 7.5 g T gel daily (75 mg delivered). The IT-T concentrations obtained by percutaneous testicular aspiration with simultaneous serum protein and steroid concentrations were measured at baseline and after 10 days of treatment. MAIN OUTCOME MEASURE(S): Intratesticular and serum hormone and gonadotropin concentrations. RESULT(S): After 10 days of gonadotropin suppression, serum INSL3 decreased by more than 90% and correlated highly with IT-T concentrations. In contrast, serum inhibin B, antimüllerian hormone, and 17α-hydroxyprogesterone did not correlate with IT-T. Serum INSL3 increased with the dose of hCG administered and returned to baseline after treatment. CONCLUSION(S): Serum INSL3 correlates highly with IT-T and serum T concentrations during acute gonadotropin suppression in men. Human chorionic gonadotropin stimulates dose-dependent increases in INSL3 and IT-T in healthy men and might be a useful biomarker of IT-T concentration in some clinical settings. CLINICAL TRIAL REGISTRATION NUMBER: NCT# 00839319.
Authors: Andrea D Coviello; Alvin M Matsumoto; William J Bremner; Karen L Herbst; John K Amory; Bradley D Anawalt; Paul R Sutton; William W Wright; Terry R Brown; Xiaohua Yan; Barry R Zirkin; Jonathan P Jarow Journal: J Clin Endocrinol Metab Date: 2005-02-15 Impact factor: 5.958
Authors: B D Anawalt; R A Bebb; A M Matsumoto; N P Groome; P J Illingworth; A S McNeilly; W J Bremner Journal: J Clin Endocrinol Metab Date: 1996-09 Impact factor: 5.958
Authors: Robert I McLachlan; Liza O'Donnell; Peter G Stanton; Georgia Balourdos; Mark Frydenberg; David M de Kretser; David M Robertson Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Jonathan T Haselman; Patricia A Kosian; Joseph J Korte; Allen W Olmstead; Sigmund J Degitz Journal: Aquat Toxicol Date: 2018-04-03 Impact factor: 4.964